Overdiagnosis in breast imaging by Evans, Andy & Vinnicombe, Sarah
                                                              
University of Dundee
Overdiagnosis in breast imaging
Evans, Andy; Vinnicombe, Sarah
Published in:
Breast
DOI:
10.1016/j.breast.2016.10.011
Publication date:
2017
Document Version
Peer reviewed version
Link to publication in Discovery Research Portal
Citation for published version (APA):
Evans, A., & Vinnicombe, S. (2017). Overdiagnosis in breast imaging. Breast, 31, 270-273. DOI:
10.1016/j.breast.2016.10.011
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 07. Nov. 2017
1 
Overdiagnosis in Breast Imaging 
Andy Evans  Sarah Vinnicombe 
© <2017>. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://
creativecommons.org/licenses/by-nc-nd/4.0/ 
2 
 
Abstract 
The main harm of overdiagnosis is overtreatment.  However a form of overdiagnosis also occurs when 
foci of cancer are found by imaging in addition to the symptomatic lesion when this leads to additional 
treatment which does not benefit the patient.   Even if overtreatment is avoided, knowledge of the 
diagnosis can still cause psychological harm.  
Overdiagnosis is an inevitable effect of mammographic screening as the benefit comes from diagnosing 
breast cancer prior to clinical detectability. Estimates of the rate of overdiagnosis at screening are 
around 10%.  DCIS represents 20% of cancers detected by screening and is the main focus in the 
overdiagnosis debate. Detection and treatment of low grade DCIS and invasive tubular cancer would 
appear to represent overdiagnosis in most cases.  Supplementary screening with tomosynthesis or US 
are both likely to increase overdiagnosis as both modalities detect predominantly low grade invasive 
cancers.  MRI causes overdiagnosis because it is so sensitive that it detects real tumour foci which after 
radiotherapy and systemic therapy do not, in many cases go on and cause local recurrence if the women 
had had no MRI and undergone breast conservation and adjuvant therapy with these small foci left in 
situ. 
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Key points 
1. Overdiagnosis is an inevitable effect of mammographic screening 
2. Detection of low grade DCIS and tubular cancer usually represents overdiagnosis  
3. Supplementary screening with tomosynthesis or US will increase overdiagnosis 
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Introduction 
Overdiagnosis is when disease is found which if left undiagnosed would not present clinically in the 
patient’s lifetime.   Breast imaging can result in overdiagnosis of invasive cancers, DCIS and benign 
lesions of uncertain malignant potential.  The main harm of overdiagnosis is overtreatment, i.e. women 
have surgery, radiotherapy and/or systemic therapy for disease which would not cause harm in their 
lifetime.    A form of overdiagnosis also occurs when foci of cancer are found by imaging in addition to 
the symptomatic lesion when this leads to additional treatment which does not benefit the patient.   
This is particularly an issue when using breast MRI prior to breast conserving surgery.  However a similar 
situation can occur in women who have imaging follow-up after a poor prognosis cancer which will 
eventually kill the patient, and mammographic follow-up detects impalpable good prognosis breast 
cancer elsewhere in the ipsilateral or the contralateral breast.   
Overtreatment is not the only harm of over-diagnosis.  Even if overtreatment is avoided, knowledge of 
the diagnosis can cause psychological harm to the patient and their family. Overdiagnosis can also cause 
practical problems like difficulties obtaining a mortgage or life and travel insurance.  
 
Overdiagnosis in mammographic screening 
Overdiagnosis is an inevitable effect of mammographic screening as the benefit comes from diagnosing 
breast cancer prior to clinical detectability.  The harms of such overdiagnosis have to be balanced 
against the benefits of a reduction in breast cancer mortality of about 20% in those women invited for 
screening (1).   The other major harm of screening come from false positive results.  Since the harms and 
benefits are not directly comparable, the only way to balance them is to seek the opinion of women 
who are invited for screening after they are made aware of the issues.  Overdiagnosis is a difficult 
concept to explain to non-medically trained people.  Qualitative research would appear to be key in this 
context but few resources have been spent in this way.  Work that has been done suggests that women 
are surprised by the frequency of overdiagnosis which occurs but that the impact on the intention of 
women to attend for screening is small (2,3).  
Over diagnosis is also complicated by the lack of agreement on how and when to calculate 
overdiagnosis.  If overdiagnosis is measured immediately after screening ceases then estimates will be 
very high as all the lead time achieved will be expressed as over diagnosis. However, if overdiagnosis is 
measured 10 years after screening ceases or at death so allowing the compensatory drop in incidence to 
occur once screening ceases, then estimates will be lower, and true over diagnosis will measured or 
estimated.  Estimates of the rate of overdiagnosis if a compensatory drop is taken into account in most 
studies are around 10% (4-5). The overdiagnosis rate when screening women aged 40-49 is as low as 1% 
(6). Overdiagnosis becomes commoner when screening older women as more women die with breast 
cancer rather than of breast cancer as decreased life expectancy and more indolent invasive breast 
cancer biology combine.  
DCIS and over diagnosis 
DCIS represents 20% of cancers detected by screening and is the main focus for many in the 
overdiagnosis debate.   Mammography has a high sensitivity for high grade DCIS with necrosis as such 
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disease readily calcifies, but low sensitivity for detecting low grade DCIS  as often such disease does not 
calcify (7).  This explains why 70% of screen detected DCIS is high grade.   This means that DCIS detection 
and treatment at screening will differentially prevent the occurrence of high grade invasive cancers 
since high grade DCIS is associated with high grade invasive cancers.  This should lead to benefits in a 
short period and not be associated high rates of over diagnosis. However this does not mitigate the 
harms due to overdiagnosis caused by the detection of low grade DCIS which represents about 15% of 
screen detected DCIS and 3% of all screen detected cancer.  Many such cases represent overdiagnosis.   
The LORIS trial which randomises women between surgical therapy and active monitoring continues to 
be an important study which deserves the support of those working in screening (8).   
A recent study has shown an association between DCIS detected at screening and a reduction in invasive 
interval cancers in the following three years.  The short time interval in which this effect is shown 
demonstrates that high grade DCIS (which represents the majority of screen detected DCIS) has the 
potential to become invasive and symptomatic in a short time period. What has not been addressed by 
this paper is the effect of DCIS detection on invasive cancer detection at the subsequent screening 
round and beyond (9).  Detection of DCIS at screening is therefore helpful for the majority of women but 
causes overdiagnosis in a minority.  Reducing this harm by not over-treating cases of screen detected 
low grade DCIS must remain a priority.  
How different terminology for ductal carcinoma in situ (DCIS) impacts on women's concern and 
management preferences is also an important issue.  A qualitative study found that communicating a 
diagnosis of DCIS using terminology that does not include the cancer term was preferred by many 
women and may enable discussions about more conservative management options (10). 
Tubular cancer 
Tubular cancers are excellent prognosis invasive cancers which represent about 2% of symptomatic 
invasive cancers and 10% of screen detected invasive cancers.  A large study has shown that breast 
cancer death only occurs if women who have had a tubular cancer develop a subsequent more 
aggressive cancer (11).  Another study found women with tubular cancer to have the same survival as 
women with DCIS with no breast cancer deaths in the follow-up period (12).  These finding are surprising 
as about 5% of women with tubular cancer have axillary metastases.  Unless tubular cancer undergoes 
phenotypic drift and develops into less differentiated cancers if left in situ, then detecting tubular 
cancers at screening will have no impact on breast cancer mortality and will represent overdiagnosis in 
the majority of cases, as symptomatic tubular cancers are rare.  However many ductal cancers on no 
specific type have a tubular component suggesting they may have arisen from a tubular cancer.  The 
frequency of tubular carcinoma de-differentating into a more aggressive cancer if left in situ is currently 
unknown.  Tubular cancers are currently treated in the same way as other invasive cancers with whole 
breast radiotherapy following wide local excision.  This appears to represent overtreatment.   
Tomosynthesis and overdiagnosis 
Digital Breast Tomosynthesis (DBT) is a new three-dimensional breast imaging technique using upgraded 
digital mammography equipment and software to present a series of “slices”, similar to MRI and CT 
scans. DBT technology is designed to overcome the problem of overlapping tissue on mammograms and 
potentially improve the ability to diagnose both abnormal and normal breasts. DBT involves taking 
multiple images of the breast from different angles, which are then digitally reconstructed into “slices”. 
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Recent studies have shown that in a screening setting DBT detects more cancers than full field digital 
mammography (FFDM)(13,14) and in units with high recall rates DBT also lowers recall rates.  No 
randomised controlled trial of mammography vs DBT has been performed so the effect of screening 
with DBT on breast cancer mortality is unknown.  Nearly all the cancers detected by DBT but not 
diagnosed on FFDM are found because subtle spiculate lesions are identified on the DBT images. 
Spiculation is a feature of low grade invasive cancers and is uncommon in grade 3 cancers.  So it is not 
surprising that the additional cancers identified by DBT are mainly grade 1 and 2 invasive cancers.  Even 
when histological grade is taken into account in a multivariate analysis spiculation maintains an 
independent good prognostic effect (15).  This may be because basal like cancers spiculate less than 
other cancers even when corrected for grade, and basal like cancers are known to have a poor outcome 
(16).  
This good prognostic profile of the additional cancers detected by DBT raises the possibility that 
screening with DBT will increase the rate of overdiagnosis compared with screening women with FFDM 
alone. The screening studies of DBT will be able to measure the interval cancer rate and compare this 
with the interval cancer rate prior to the introduction of DBT.     If the interval cancer rate drops then 
one could argue that screening DBT is detecting at least some biologically important cancers and so may 
impact on breast cancer mortality.  If the interval cancer rate remains unchanged then it could be 
argued that screening DBT is predominantly increasing overdiagnosis and is unlikely to impact on breast 
cancer mortality.    A recent US study has shown a trend towards a lower interval cancer rate following 
the introduction of tomosynthesis screening (17). 
Ultrasound (US) screening and over diagnosis 
Screening women with mammographically dense breasts using bilateral US has many advocates.  This is 
because mammographic sensitivity is reduced in women with dense breasts and breast density is also a 
significant risk factor for breast cancer (18).  The masking effect of breast density means that in women 
with dense breasts, the lead time of screening is shortened and the mean size of cancers detected is 
larger (19). One issue is the lack of a standardised definition of a dense breast, since visual breast 
density assessment has very poor reproducibility (20). Supplementary screening with US has been 
shown to significantly increase the invasive cancer detection rates and most of the additional cancers 
detected are small and node negative.  Only about 10% of additional cancer detected by US screening 
are DCIS. The downside of supplementary US screening is the very poor specificity and the time needed 
to scan both breasts.  Less than 1 in 10 US screening provoked biopsies shows cancer. There are no RCT 
trials of supplementary US screening designed to measure breast cancer mortality. 
To what degree are the additional cancer detected by supplementary US screening likely to contribute 
to additional overdiagnosis? A recent RCT has shown that such screening significantly reduces the 
interval cancer rate, implying that at least some of the cancers detected by US screening are biologically 
important (21).  Unfortunately this study did not publish the grade distribution of the additional cancers 
detected by US screening, which would have helped assessment of possible overdiagnosis.  A previous 
Italian study showed a similar drop in interval cancer rates in women given supplemental ultrasound 
screening (22).  On the other hand, in the ACRIN 6666 Trial almost half (46%) of the additional invasive 
cancers found were grade 1 compared to 19% of those cancer detected by mammography alone and 
25% of those detected by both modalities (23).  This is not surprising as the US characteristics of low 
grade cancers are more suspicious than those of high grade cancers. So despite reducing interval cancer 
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rates, supplemental screening of women with dense breasts is likely to significantly increase 
overdiagnosis compared to women screened by mammography alone.  
MRI and over diagnosis 
Breast MRI is now widely used for high risk screening, assessing breast implants, monitoring 
neoadjuvant chemotherapy and local staging.  Its widespread use to locally stage breast cancer prior to 
breast conserving surgery is controversial as the multicentre randomised controlled COMICE study 
showed that MRI use did not reduce re-operation rates (24).  MRI use in this clinical setting has also 
been shown to be associated with increased mastectomy rates (25) but not a reduction in local 
recurrence or disease free survival (26, 27).  The problem is not that MRI gives false positive results, but 
that it is so sensitive that it detects real tumour foci which after radiotherapy and systemic therapy do 
not, in many cases go on and cause local recurrence if the women had had no MRI and undergone 
breast conservation and adjuvant therapy with these small foci left in situ.  Currently however it is 
impossible to tell which foci will or will not go on to cause local recurrence.   So with current treatment 
protocols, many of the addition tumour foci detected by MRI represent over diagnosis as they lead to 
over- treatment.   However MRI also gives the opportunity to give less treatment to women with truly 
uni-focal tumours.  Intra-operative radiotherapy and partial breast irradiation are associated with less 
morbidity than whole breast radiotherapy so may be particularly appropriate in women who have a 
unifocal tumour on MRI.  Unfortunately the TARGIT trial of intraoperative radiotherapy (IORT) did not 
use MRI to confirm true unifocality so this may be why the TARGIT-A trial has a higher local recurrence 
rate in women treated with IORT compared to those women given whole breast radiotherapy (28).   
A recent study of staging MRI in older women has shown that an increased synchronous contralateral 
breast cancer detection rate, attributable to MRI, was not offset by a decrease of subsequent 
contralateral breast cancer occurrence among older women with early-stage breast cancer, suggesting 
that preoperative MRI in older women with breast cancer may lead to significant overdiagnosis (29). 
MRI detects virtually all invasive breast cancers so the trend to preferential detection of low grade 
invasive cancers seen with mammography and ultrasound is not present with MRI.  MRI also tends to 
identify high grade DCIS more than low grade DCIS so MRI detected DCIS is not a source of major 
overdiagnosis.  
Conclusion 
The use of any breast imaging technique can lead to overdiagnosis and overtreatment.  Currently our 
ability to detect disease is not matched by our ability to predict disease behaviour.  This leads to 
overtreatment in many cases.  The harms of overdiagnosis need to balanced against the benefits of 
using imaging techniques.  Knowing more is only helpful when you know what to do with the 
information gained.  This is currently not always the case with breast imaging.  
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